NCI-2023-10167

Phase II Single-Arm Study of Durvalumab and Bevacizumab Following Transarterial Radioembolization Using Yttrium-90 Glass Microspheres (TheraSphere) in Unresectable Hepatocellular Carcinoma Amenable to Locoregional Therapy (EMERALD-Y90)

This Phase 2 research study is investigating the combined effect of Durvalumab and Bevacizumab immunotherapy after patients with unresectable liver cancer (HCC) have undergone TARE using Yttrium-90 glass microspheres. Transarterial Radioembolization (TARE) is a procedure where a catheter is inserted into an artery in the groin and threaded to the arteries supplying the liver tumor. Radioactive microspheres containing Yttrium-90 (the TheraSphere) are released into the arteries, delivering high doses of radiation directly to the tumor while limiting exposure to healthy liver tissue. Durvalumab is an immunotherapy drug called a checkpoint inhibitor. It works by helping the body's immune system recognize and attack cancer cells. It targets the PD-1 protein on cancer cells, which normally helps cancer evade immune attack. Bevacizumab is a targeted therapy drug called an angiogenesis inhibitor. It works by blocking the growth of new blood vessels that tumors need to grow. The study aims to see if this combination is effective in treating this type of liver cancer that cannot be surgically removed

Immunotherapy: The immune system helps fight cancer by sending the body's defense (immune) system to kill the cancer cells. Immunotherapy drugs target cancer cells to prevent them from multiplying and growing.

Unresectable: Unable to be removed through surgery

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT06040099

Clinical Trial Site: Sinai

To see all available clinical trials click here.